| |
| |
RED Abemaciclib
|
| NICE TA563 Recommended, within its marketing authorisation, with an aromatse inhibitor, as an option for treating locally |
| advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2) - negative |
| breast cancer as first endocrine-based therapy in adults. (only recommended if the company provides it according to |
| the commercial arrangement. Cancer Drugs Fund |
| NICE TA579 Abemaciclib with fulvestrant - this guidance has been replaced by NICE TA725 [15th September 2021] |
| |
| NICE TA725 Abemaciclib with fulvestrant is recommended as an option for treating hormone receptor-positive, human |
| epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults who have had |
| endocrine therapy only if: |
| > exemestane plus everolimus is the most appropriate alternative to a cyclin‑dependent kinase 4 and 6 (CDK 4/6) |
| inhibitor and |
| > the company provides abemaciclib according to the commercial arrangement. |
| NHS England Commissioned |
| RED Abemaciclib [Verzenios] |
| NICE TA810 Abemaciclib with endocrine therapy is recommended, within its marketing authorisation, as an option for |
| adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer in adults whose |
| disease is at high risk of recurrence, defined by the following clinical and pathological features: |
| > at least 4 positive axillary lymph nodes, or |
| > 1 to 3 positive axillary lymph nodes, and at least one of the following criteria: |
| - grade 3 disease (defined as at least 8 points on the modified Bloom-Richardson grading system or |
| equivalent), or |
| - primary tumour size of at least 5cm. |
| See full guidance NHS England Commissioned |
RED Acalabrutinib [Calquence®] |
| NICE TA689 Recommended as an option, as monotherapy, for untreated chronic lymphocytic leukaemia (CLL) in adults, only if: |
| > there is a 17p deletion or TP53 mutation, or |
| > there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab, or |
| bendamustine plus rituximab is unsuitable, and |
| the company provides the drug according to the commercial arrangement. NHS England Commissioned |
RED Alectinib |
NICE TA536 Recommended as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell
|
| cancer in adults. NHS England Commissioned |
| |
RED Alpelisib [Piqray] plus fulvestrant |
| NICE TA816 Recommended as an option for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally |
| advanced or metastatic breast cancer in adults, only if: |
| > their cancer has progressed after a CDK4/6 inhibitor plus ab aromatose inhibitor and |
| > the company provides alpelisib according to the commercial arrangement |
| This guidance updates and replaces TA652 on apelisib with fulvestrant [terminated appraisal] |
| NHS England Commissioned |
RED Arsenic trioxide |
NICE TA526 Recommended, within its marketing authorisation, as an option for inducing remission and consolidation in
|
acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha
|
gene) in adults with:
|
> untreated, low-to-intermediate risk disease (defined as a white blood cell count of 10x10³ per microlitre or less),
|
when given with all-trans-retinoic acid (ATRA)
|
> relapsed or refractory disease, after a retinoid and chemotherapy NHS England Commissioned
|
| RED Asciminib [Scemblix] |
| NICE TA813 Asciminib is recommended, within its marketing authorisation, as an option for treating chronic-phase Philadelphia |
| chromosome-positive chronic myeloid leukaemia without a T315l mutation after 2 or more tyrosine kinase inhibitors in |
| adults. It is recommended only if the company provides asciminib according to the commercial arrangement. |
| NHS England Commissioned |
RED Atezolizumab |
NICE TA520 For treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy.
|
| Recommended as an option in in adults who have had chemotherapy (and targeted treatment if they have |
| an EGFR- or ALK‑positive tumour), only if: |
| > atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and |
| > the company provides atezolizumab with the discount agreed in the patient access scheme. |
| (NHS England Commissioned) |
NICE TA525 For treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
|
| Recommended as an option in only if: |
| > atezolizumab is stopped at 2 years of interrupted treatment or earlier if the disease progresses and |
| > the company provides atezolizumab with discount agreed in the patient access scheme |
| (NHS England Commissioned) |
NICE TA584 Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for metastatic non-
squamous on-small-cell lung cancer (NSCLC)in adults: |
| > who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is |
| between 0% and 49% or |
| > when targetted therapy for epidermal growth factor receptor (EGFR)-positive or anaplastic lymphoma kinase |
(ALK)-positive NSCLC has failed.
|
| It is recommended only if: |
| > atezolizumab and bevacizumab are stopped at 2 years of uninterrupted treatment, or earlier if there is loss of |
| clinical benefit (for atezolizumab) or if the disease progresses (for bevacizumab) and |
| > if the company provides atezolizumab and bevacizumab according to the commercial arrangements. |
| NICE TA638 Atezolizumab with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell |
| lung cancer in adults, only if: |
| > they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and |
| > the company provides atezolizumab according to thecommercial arrangement |
| |
| NICE TA639 Atezolizumab with nab-paclitaxel is recommended, within its marketing authorisation, for treating triple negative, |
| unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults whose tumours express PD-L1 at a |
| level of 1% or more and who have not had previous chemotherapy for metastatic disease. It is recommended only if |
| the company provides atezolizumab according to the commercial arrangement |
| NICE TA666 Atezolizumab plus bevacizumab is recommended as an option for treating advanced or unresectable hepatocellular |
| carcinoma [HCC] in adults who have not had previous systemic treatment, only if: |
| > they have Child-Pugh grade liver impairment and an Eastern Cooperative Oncology Group [ECOG] performance |
| status of 0 or 1 and |
| > the company provides it according to the commercial arrangement (NHS England Commissioned) |
| NICE TA705 Atezolizumab is recommended within its marketing authorisation, as an option for untreated metastatic non-small-cell |
| lung cancer in adults if: |
| > their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells |
| > their tumours do not have epidermal growth factor receptor or anaplastic lymphoma kinase mutations and |
| > the company provides atezolizumab according to the commercial arrangement. (NHS England Commissioned) |
| NICE TA823 Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for adjuvant treatment after |
| complete tumour resection in adults with stage 2 to 3a non-small-cell lung cancer (NSCLC) whose: |
| > tumours have the programmed cell death ligand‑1 (PD‑L1) biomarker expression on 50% or more of their tumour |
| cells and |
| > whose disease has not progressed after platinum-based adjuvant chemotherapy. |
| It is recommended only if the company provides atezolizumab according to the managed access agreement. |
| Cancer Drugs Fund |
RED Axicabtagene ciloleucel therapy |
| NICE TA872 Recommended, within its marketing authorisation, as an option for treating relapsed or refractory diffuse large B-cell lymphoma or primary |
| mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies. It is recommended only if the company provides |
| axicabtagene ciloleucel according to the commercial arrangement. NHS England Commissioned |
| This guidance updates and replaces NICE TA559 |
| |
RED Axitinib
|
NICE TA333 Recommended as an option for treating adults with advanced renal cell carcinoma after failure of treatment with a
|
| first line tyrosine kinase inhibitor or a cytokine, only if the compant provides axitinib with the discount agreed in the |
| patient access scheme. |
RED Bortezomib
|
| NICE TA129 Recommended as an option for the treatment of progressive multiple myeloma in people who are at first relapse |
| having received one prior therapy and who have undergone, or are unsuitable for, bone marrow transplant, under the |
| circumstances listed in the guidance. |
| NICE TA228 Bortezomib and thalidomide for the first-line treatment of multiple myeloma: |
| 1. Thalidomide in combination with an alkylating agent and a corticosteroid is recommendaed as an option for the first |
| line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is |
| considered inappropriate |
| 2. Bortezomib in combination with an alkylating agent and a cortiscosteroid is recommended as an option for the |
| first-line treatment of multiple myeloma if: |
| > a high dose chemotherapy with stem cell transplantation is considered inappropraite and |
| > the person is unable to tolerate or has contraindications to thalidomide |
| NICE TA311 Recommended as an option within its marketing authorisation, that is, in combination with dexamethasone, or with |
| dexamethasone and thalidomide, for the induction treatment of adults with previously untreated multiple myeloma, |
| who are eligible for high-dose chemotherapy with haematopoietic stem cell transplant. |
| NICE TA370 Recommended, within its marketing authorisation, as an option for previously untreated mantle cell lymphoma in |
| adults for whom haemotopoietic stem cell transplantation is unsuitable. |
RED Bosutinib (Bosulif)
|
| NICE TA401 Recommended as an option, within its marketing authorisation, for chronic accelerated and blast phase Philadelphia |
| chromosome positive chronic myeloid leukaemia in adults, when: |
| > they have previously had 1 or more tyrosine kinase inhibitor and |
> imatinib, nilotinib and dasatinib are not appropriate and
|
> the company provides bosutinib with the discount agreed in the patient access scheme (as revised in 2016)
|
RED Brentuximab vedotin (Adcetris®)
|
| NICE TA524 Recommended as an option for treating CD30- positive Hodgkin Lymphoma in adults with relapsed or refractory |
| disease only as specified in NICE TA524 |
| This guidance is a Cancer Drugs Fund reconsideration of NICE TA446 and replaces TA446 |
| (NHS England Cancer Drugs Fund) |
NICE TA478 Recommended as an option for treating relapsed or refractory systemic anapplastic large cell lymphoma in adults
|
| (NHS England Commissioned) |
| NICE TA577 Recommended as an option for treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 systemic |
| therapy in adults, only if: |
| > they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma |
or Sézary syndrome and
|
| > the company prvides brentuximab vedotin according to the commercial arrangement |
| NICE TA641 Recommended within its marketing authorisation, with cyclophosphamide, doxorubicin and prednisolone, as an |
| option for untreated systemic anaplastic large cell lymphoma in adults. (NHS England Commissioned) |
| |
|
RED Brexucabtagene autoleucel (Tecartus) |
|
NICE TA893 Recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B‑cell acute |
| lymphoblastic leukaemia in people 26 years and over. It is recommended only if the conditions in |
| the managed access agreement for brexucabtagene autoleucel are followed. NHSE Cancer Drug Fund |
RED Brigatinib (Alunbrig) |
| NICE TA571 Recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced |
| non-small-cell lung cancer in adults who have already had crizotinib, It is recommended only if the company |
| provides it according to the commercial arrangement. (NHS England Commissioned) |
| NICE TA670 Recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase [ALK]-positive advanced |
| non-small-cell lung cancer that has not been previously treated with an ALK inhibitor in adults |
| (NHS England Commissioned) |
RED Cabazitaxel
|
NICE TA391 In combination with prednisone or prednisolone is recommended an option for treating metastatic hormone-relapsed
|
| prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy. |
RED Cabozantinib |
NICE TA463 An option for treating advanced renal cell carcinoma in adults after vascular endothelial growth factor- targeted
|
| therapy. (NHS England Commissioned) |
NICE TA516 Recommended , within its marketing authorisation, as an option for treating progressive medullary thyroid cancer in
|
| adults with unresectable, locally advanced or metastatic disease. (NHS England Cancer Drugs Fund) |
| NICE TA 849 Recommended as an option for treating advanced hepatocellular carcinoma in adults who have had sorafenib, only if: |
| > they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and |
| > the company provides it according to the commercial arrangement. |
| NICE TA849 updates and replaces NICE TA542 NHS England Commissioned |
| |
RED Carboplatin injection 150mg/15mL, 450mg/45mL
|
RED Carfilzomib powder For solution for infusion |
NICE TA657 Recommended as an option in combination with dexamethasone for treating multiple myeloma in adults only if:
|
| > they have had only 1 previous therapy, which did not include bortezomib and |
| > the company provides carfilzomib with the discount agreed in the patient access scheme. |
| NICE TA657 updates and replaces TA457 NHS England Commissioned |
| |
| NICE TA695 Recommended as an option with lenalidomide and dexamethasone for treating multiple myeloma in adults, only if: |
| > they have had only 1 previous therapy, which included bortezomib, and |
| > the company provides carfilzomib according to the commercial arrangement |
| Partially updates NICE TA657 NHS England Commissioned |
RED Cemiplibab |
| NICE TA592 updated and replaced by NICE TA802 |
| NICE TA802 Recommended as an option for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
| in adults when curative surgery or curative radiotherapy is not suitable, only if: |
| > it is stopped at 24 months, or earlier if their disease progresses, and |
| > the company provides cemiplimab according to the commercial arrangement |
| This guidance updates and replaces NICE TA592 |
RED Ceritinib |
NICE TA395 Recommended within its marketing authorisation, as an option for treating advanced anaplastic lymphoma
|
| kinase positive non-small-cell lung cancer in adults who have previously had crizotinib. The drug is recommended |
| only if the company provides it with the discount agreed in the patient access scheme. |
NICE TA500 Recommended within its marketing authorisation, as an option for untreated anaplastic kinase (ALK)-positive
|
| advanced non-small-cell cancer in adults, only if the company provides it with the discount agreed in the patient |
| access scheme. (NHS England Commissioned) |
RED Cetuximab infusion 5mg/mL
|
NICE TA439 (updated Sept 2017) Cetuximab and panitumumab is recommended, as an option for previously untreated
|
| metastatic colorectal cancer |
NICE TA473 In combination with platinum based chemotherapy is recommended as an option for treating recurrent or metastatic
|
| squamous cell cancer of the head and neck in adults only. (NHS England Commissioned) |
RED Cisplatin injection 50mg
|
RED Crizotininb capsules 200mg, 250mg
|
NICE TA406 Recommended as an option, within its marketing authorisation, for untreated anaplastic lymphoma kinase-positive
|
| advanced non-small-cell cancer in adults. (NHS England Commissioned) |
NICE TA422 An option in previously treated anaplastic lymphoma kinase-positive advanced on-small-cell lung cancer in adults
|
NICE TA529 Recommended for use within the Cancer Drugs Fund as an option for treating ROS1- positive advanced
|
| non-small-cell lung cancer in adults only if the conditions in the managed access agreement are followed. |
| (NHS England Cancer Drugs Fund) |
RED Dabrafenib
|
NICE TA321 Recommended as an option, within its marketing authorisation, for treating unrescectable or metastatic BRAF V600
|
| mutation-positive melanoma [only if the company provides darafenib with the discount agreed in the patient access |
| scheme. |
| NICE TA544 Dabrafenib with trametinib is recommended, within its marketing authorisation, an option for the adjuvant treatment |
| of resected stage III BRAF V600 mutation-positive melanoma in adults as per (NHS England Commissioned) |
| NICE TA898 Dabrafenib plus trametinib is recommended as an option for treating BRAF V600 mutation-positive advanced |
| non-small-cell cancer in adults, only if: |
| > it is used as first-line treatment of advanced stage cancer, and |
| > the company provides it according to the commercial arrangement. |
| This guidance updates and replaces NICE TA564 |
RED Dacomitinib tablets 45mg (Vizimpro®) |
| NICE TA595 Recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic |
| epidermal growth factor receptor [EGFR] mutation-positive non-small-cell lung cancer in adults. It is recommended |
| only if the company provides it according to the commercial arrangement. (NHS England Commissioned) |
RED Daratumumab |
| NICE TA510 This guidance has been updated and replaced by NICE TA783 |
|
| NICE TA573 This guidance has been updated and replaced by NICE TA897 |
| |
| NICE TA763 Daratumumab plus bortezomib, thalidomide and dexamethasone is recommended, within its marketing |
authorisation, as induction and consolidation treatment for untreated multiple myeloma in adults, when an
|
autologous stem cell transplant is suitable. NHS England Commissioned
|
| NICE TA783 Daratumumab monotherapy is recommended as an option for treating relapsed and refractory multiple myeloma in |
| adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last |
| treatment, only if: |
| > they have daratumumab after 3 treatments and |
| > the company provides daratumumab according to the commercial arrangement |
| Replaces NICE TA510 |
| NICE TA897 Daratumumab with bortezomib and dexamethasone is recommended as an option for treating multiple myeloma in |
| adults, only if they have had just 1 previous line of treatment and: |
| > it included lenalidomide or |
| > lenalidomide is unsuitable as a second-line treatments and |
| > the company provides it according to the commercial arrangement. |
| This guidance updates and replaces NICE TA573 NHS England Commissioned |
RED Dasatinib |
NICE TA425 Dasatininb is recommended as an option in treating only chronic- or accelerated-phase Philadelphia-chromosome-
|
positive chronic myeloid leukaemia in adults. [Replaces NICE TA241] (NHS England Commissioned)
|
NICE TA426. Dasatinib is recommended as an option for untreated chronic-phase Philadelphia- chromosome-positive
|
| chronic myeloid leukaemia in adults [Replaces NICE TA251} (NHS England Commissioned) |
RED Dacarbazine injection 1g
|
RED Dinutuximab beta |
NICE TA538 Dinutuximab is recommended as an option for treatin g high-risk neuroblastoma in people aged 12 months and
|
| over whose disease has at least partially responded to induction chemotherapy, followed by myeloablative therapy |
and stem cell transplant (NHS England Commissioned)
|
RED Docetaxel injection 20mg/0.5ml, 80mg/2ml (NICE indications only)
|
| |
RED Dostarilumab |
| NICE TA779 Dostarilumab is recommended for use within the Cancer Drugs Fund as an option for treating advanced or recurrent |
| endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had |
| platinum-based chemotherapy. It is recommended only if the conditions in the managed access agreement are |
| followed, Cancer Drugs Fund |
RED Encorafenib |
NICE TA562 Encorafenib with binimetinib is recommended, within its marketing authorisation, as an option for treating
|
| unresectable or metastatic BRAF V600 mutation-positive melanoma in adults. (NHS England Commissioned) |
NICE TA668 Encorafenib plus cetuximab is recommended, within its marketing authorisation, as an option for treating
|
BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.
|
| (NHS England Commissioned) |
RED Entrectinib [Rozlytek] |
| NICE TA643 Recommended within its marketing authorisation, as an option for treating ROS1-positive advanced non-small-cell |
| lung cancer in adults who have not had ROS1 inhibitors. (NHS England Commissioned) |
| NICE TA644 Recommended for use within the Cancer Drugs Fund as an option for treating neurotropic tyrosine receptor kinase |
| [NTRK] fusion-positive solid tumours in adults and children 12 years and older if; |
| > the disease is locally advanced or metastatic or surgery could cause severe health problems and |
| > they have not had and NTRK inhibitor before and |
| > they have no satisfactory treatment options (Cancer Drugs Fund) |
RED Eribulin solution for injection 0.8mg/2ml, 1.32mg/3ml. |
NICE TA423 Eribulin is recommended as an option for treating locally advanced or metastatic breast cancer in adults who have
|
had 2 or more courses of chemotherapy. (replaces NICE TA250) (NHS England Commissioned)
|
RED Erlotinib tablets 25mg, 100mg, 150mg (NICE indication only)
|
NICE TA374 Erlotinib is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer
|
| that has progressed after prior chemotherapy. (NHS England Commissioned) |
RED Everolimus 2.5mg, 5mg, 10mg tablets, |
NICE TA421 in combination with exemestane is recommended as an option for treating advanced breast cancer after
|
| endocrine therapy (NHS England Commissioned) |
NICE TA432 recommended as an option for treating advanced renal cell carcinoma that has progressed during or after treatment
|
| with vascular endothelial growth factor targeted therapy, only if the company provides it with the discount agreed in |
| the patient access scheme. (NHS England Commissioned) |
| NICE TA449 unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease. |
| (NHS England Commissioned) |
| |
RED Fedratinib [Inrebic] capsules 100mg |
| NICE TA756 Recommended for use within the Cancer drugs Fund as an option for treating disease-related splenomegaly of |
| primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocytopenia myelofibrosis |
| in adults. It is recommended only if: |
| > they have previously had ruxolitinib and |
| > the conditions in the managed access agreement for fedratinib are followed. |
| Cancer Drugs Fund |
RED Gilteritinib [Xospata] 40mg tablets |
| NICE TA642 Recommended as an option for treating relapsed or refractory FLY3-mutation-positive acute myeloid leukaemia in |
| adults only if the company provides gilteritinib according to the commercial arrangement. |
| (NHS England Commissioned) |
RED Hydroxycarbamide capsules 500mg - unlicensed use for psoriasis in adults. Specialist initiation only. |
|
RED Gefitinib tablets 250mg
|
RED Gemtuzumab oxogamicin |
NICE TA545 with daunorubicin and cytarabine is recommended as an option for untreated de novo CD33-positive acute myeloid
|
| leukaemia in people aged 15 years and over. (NHS England Commissioned) |
RED Ibrutinib capsules 140mg as an option for treating chronic lymphocytic leukaemia in adults who have had at least 1
|
| prior therapy or, who have a 17p deletion or TP53 mutation, and in whom chemotherapy is unsuitable as per |
| NICE TA429 (NHS England Commissioned) |
| Ibrutinib NICE TA491 this has been updated and replaced by NICE TA795 [BLACK TRAFFIC LIGHT: |
| |
| RED Ibrutinib is recommended as an option for treating relapsed or refractory mantle cell lymphoma in adults only if they |
have had 1 previous line of therapy and the company provides ibrutinib with the agreed discount in the commercial
|
| access agreement with NHS England as in NICE TA502 (NHS England Commissioned) |
|
| RED Ibrutinib with venetoclax is recommended, within its marketing authorisation, as an option for untreated chronic |
| lymphocytic leukaemia (CLL) in adults. This is only if the companies provide both drugs according to the commercial |
| arrangements. NICE TA891 NHS England Commissioned |
RED Idelalisib (Zydelig®) tablets 100mg, 150mg - as an option in NICE TA359 for treating chronic lymphocytic leukaemia |
|
RED Imatinib [Glivec]
|
NICE TA326 Recommended as an option as adjuvant treatment for up to 3 years for adults who are at high risk of relapse
|
| after surgery for KIT (CD117)-positive gastrointestinal stromal tumours, as defined by the Miettinen 2006 crtieria |
| (based on tumour size, location and mitotic rate). |
NICE TA425 This guidance replaces NICE TA421 (NHS England Commissioned)
|
| |
| NICE TA426 Recommended as an option for untreated, chronic-phase Philadelphia-chromosome- positive chronic myeloid |
| leukaemia in adults |
RED Ipilimumab IV infusion 5mg/mL (NICE indications only as below)
|
| NICE TAG319 as an possible treatment in previously untreated advanced (unresectable or metastatic) melanoma |
| NICE TA268 as a possible treatment for people with previously treated advanced (unresectable or metastatic) |
| melanoma. |
RED Irinotecan concentrate for infusion 20mg/mL (NICE indication only)
|
| |
RED Isatuximab [Sarclisa®] (NHS England Commissioned) |
| NICE TA658 Isatuximab plus pomalidomide and dexamethasone is recommended for use within the Cancer Drugs fund, as an |
| option for treating relapsed and refractory multiple myeloma in adults who have had lenalidomide and a |
proteasome inhibitor, and whose disease has progressed on their last treatment, only if:
|
| > they have had 3 previous lines of treatment |
| > the conditions in the managed access agreement for isatuximab plus pomalidomide and dexamethasone are |
| followed. |
RED Ixazomib with lenalinomide and dexamethasone {Ninlaro) | NICE TA870 Recommended as an option for treating relapsed or refractory multiple myeloma in adults, only if:
| | > they have had 2 or 3 lines of therapy and | | > the company provides ixazomib according to the commercial arrangement. | | This guidance updates and replaces NICE TA505 (NHS England Commissioned) |
|
|
| |
RED Larotrectinib |
| NICE TA630 Recommended for use within the Cancer Drugs Fund as an option for treating neurotrophic tyrosine receptor kinase |
| (NTRK) fusion-positive solid tumours in adults and children if: |
| > the disease is locally advanced or metastatic or surgery could cause severe health problems and |
| > they have no satisfactory treatment options |
| It is recommended only if the conditions in the managed access agreement for larotrectinib are followed |
RED Lenvatinib is recommended as an option for untreated, advanced, unrescetable hepatocellular carcinoma in adults, |
| as per NICE TA551 NHS England Commissioned |
| RED Lenvatinib with everolimus for previously treated advanced renal cell carcinoma as an option as per NICE TA498 |
NHS England Commissioned
|
| RED Lenvatininb and sorafenib recommended as options for treating progressive, locally advanced or metastatic |
| differentiated thyroid cancer (papillary, follicular or Hurthle cell) in adults whose disease does not respond to |
radioactive iodine - as per NICE TA535 NHS England Commissioned
|
| | | RED Lenvatinib with pembrolizumab is recommended as an option for untreated advanced renal cell carcinoma in adults, only if: | | > their disease is intermediate or poor risk a defined in the international Metastatic Renal cell Carcinoma Database Consortium criteria and | | > nivolumab with ipilimumab would otherwiae be offered and | | > the companies provide lenvatinib and pembrolizumab according to the company arrangements | | See NICE TA858 NHS England Commissioned | | |
RED Lorlatinib tablets 25mg, 100mg {Lorviqua) (NHS England Commissioned) | | NICE TA628 Recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK) - | | positive advanced small-cell lung cancer in adults whose disease has progressed after: | | > alectinib or ceritinib as the first ALK tyrosine kinase inhibitor or | | > crizotinib and at least 1 other ALK tyrosine kinase inhibitor |
RED Lutetium (177Lu) oxodotreotide recommended as an option for treating unresectable or metastatic, | |
| progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic |
| neuroendocrine tumours in adults - as per NICE TA539 (NHS England Commissioned) |
RED Midostaurin |
| NICE TA523 Recommended, within its marketing authorisation, as an option in adults for treating newly diagnosed |
| acute FLT3-mutation-positive myeloid leukaemia with standard daunorubicin and cytarabine as induction therapy, |
| with high-dose cytarabine as consolidation therapy, and alone after complete response as maintenance therapy |
| (patient access scheme) NHS England Commissioned |
| NICE TA728 Midostaurin as monotherapy is recommended, within its marketing authorisation, as an option for treating |
| aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell |
| leukaemia in adults. It is recommended only if the company provides midostaurin according to the |
| commercial arrangement. NHS England Commissioned |
RED Mobocertinib |
| NICE TA855 Mobocertinib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic non-small-cell |
| lung cancer (NSCLC) after platinum-based chemotherapy in adults whose tumours have epidermal growth factor receptor (EGFR) |
| exon 20 insertion mutations. It is recommended only if the company provides it according to the commercial arrangement. |
| NHS England Commissioned |
RED Neratinib tablets 40mg (Nerlynx) |
| NICE TA612 Recommended as an option for the extended adjuvant treatment of hormone receptor-positive, |
| human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults who completed |
| adjuvant trastuzumab-based therapy less than 1 year ago only if: |
| > trastuzumab is the only HER2‑directed adjuvant treatment they have had, and |
| > if they had neoadjuvant chemotherapy-based regimens, they still had residual invasive disease in the breast or |
| axilla following the neoadjuvant treatment, and |
| > the company provides neratinib according to the commercial arrangement. (Cancer Drugs Fund) |
RED Nilotinib capsules 150mg, 200mg as an option for untreated chronic-phase Philadelphia-chromosome- positive
|
chronic myeloid leukaemia in adults as per NICE TA426 Replaces NICE TA251 NHS England Commissioned
|
RED Nilotinib capsules 150mg, 200mg option in treating only chronic- or accelerated- phase Philadelphia- chromosome-positive chronic myeloid leukaemia in adults as per NICE TA425 Replaces NICE TA241
| | NHS England Commissioned |
RED Niraparib | | NICE TA528 This guidance has been updated and replaced by NICE TA784 | | NICE TA673 Recommended for use within the Cancer Drugs Fund as an option for maintenance treatment for advanced | | (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to | | first-line platinum-based chemotherapy in adults. It is recommended only if the managed access agreement | | for niraparib. (Cancer Drugs Fund) | | NICE TA784 Recommended as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian | | tube or primary peritoneal cancer that has responded to the most recent course of patinum-based chemotherapy | | in adults. It is recommended only if: | | > they have BRCA mutation and have had 2 courses of platinum-based chemotherapy, or | | > they do not have a BRCA mutation and have had 2 or more courses of platinum-based chemotherapy, and | | > the company provides it according to the commercial arrangement. | | This guidance updates and replaces NICE TA528 NHS England Commissioned | |
RED Nivolumab
|
NICE TA384 intravenous infusion 10mg/ml is recommended as an option by NICE for treating advanced (unresectable or metastatic) melanoma.
|
| |
NICE TA400. in combination with ipilimumab is recommended, within its marketing authorisation, as an option for treating
|
| advanced (unresectable or metastatic) melanoma in adults, only when the company provides ipilimumab with the |
| discount agreed in the patient access scheme. |
NICE TA417 recommended as an option for previously treated advanced renal cell carcinoma in adults.
|
| (updated September 2017 after a change to the commercial arrangements) |
| NICE TA462 recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous |
| stem cell transplant and treatment with brentuximab vedotin. (updated September 2017 after a change to the |
| commercial arrangements) |
NICE TA484 recommended for use within the Cancer drugs Fund as an option for treating locally advanced or metastatic
|
| non-squamous non-small-cell lung cancer in adults after chemotherapy |
| NICE TA490 Replaced by NICE TA736 |
NICE TA581 This guidance has been updated and replaced by NICE TA780
|
NICE TA655 Recommended as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer in
|
| adults after chemotherapy, only if: |
| > it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses and |
| > they have not had a PD-1 or PD-L1 inhibitor before. |
| [Replaces NICE TA483] (NHS England Commissioned) |
| NICE TA558 recommended as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node |
involvement or metastatic disease. It is recommended only if the conditions in the managed access agreement are
|
| followed. (Cancer Drug Fund) |
| NICE TA684 Recommended as an option, within its marketing authorisation, as an option for the adjuvant treatment of completely |
| resected melanoma in adults with lymph node involvement or metastatic disease. It is recommended only if the |
| company provides nivolumab according to the commercial arrangement. (Cancer Drug Fund) |
| NICE TA707 Recommended, within its marketing authorisation, for treating unresectable advanced, recurrent or metastatic |
| oesophageal squamous cell carcinoma in adults after fluoropyrimidine and platinum-based therapy. It is |
| recommended only if the company provides nivolumab according to the commercial arrangement. |
| (NHS England Commissioned) |
| NICE TA716 Recommended as an option [plus ipilimumab], within its marketing authorisation, for treating metastatic |
| colorectal cancer with high microsatellite instability [MSI] or mismatch repair [MMR] deficiency after fluoropyrimidine- |
| based combination chemotherapy only if the company provides nivolumab and ipilimumab according to the |
| commercial arrangement. (NHS England Commissioned) |
NICE TA736 Recommended as an option for treating recurrent or metastatic squamous cell carcinoma of the head and neck
| in adults whose disease has progressed on platinum-based chemotherapy, only if: | | > the disease has progressed within 6 moths of having chemotherapy and | |
| > the company provides it according to the commercial arrangement NHS England Commissioned |
| [Replaces NICE TA490] |
| NICE TA746 Recommended within its marketing authorisation, for adjuvant treatment of completely resected oesophageal |
| or gastro-oesophageal junction cancer in adults who have had residual disease after previous neoadjuvant |
| chemoradiotherapy. It is recommended only if the company provides nivolumab according to the |
| commercial arrangement. NHS England Commissioned |
| NICE TA780 Nivolumab with ipilimumab is recommended, within its marketing authorisation, as an option for untreated advanced |
| renal cell carcinoma in adults: |
| > whose disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma |
| Database Consortium criteria and |
| > only if the company provides nivolumab with ipilimumab according to the commercial arrangement. |
| This guidance updates and replaces NICE TA581 NHS England Commissioned |
| |
NICE TA857 Nivolumab with platinum- and fluoropyrimidine-based chemotherapy is recommneded, within its marketing authorisation, as an option for
untreated HEr2-negative advanced gastric, gastro-oesophageal adenocarcinoma in adults whose tumours express PD-L1 with a combined
positive score (CPS) of 5 or more. Nivolumab is only recommended if the company provides it according to the commercial arrangement. |
NHS England Commissioned
NICE TA865 Nivolumab with fluoropyrimidine-based and platinum-based combination chemotherapy is recommended as an option for untreated |
| unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD‑L1 at a level of 1% |
| or more. It is recommended only if: |
| > pembrolizumab plus chemotherapy is not suitable |
| > the company provides nivolumab according to the commercial arrangement. |
| NHS England Commissioned |
| NICE TA876 Nivolumab with chemotherapy is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of resectable |
| (tumours at least 4 cm or node positive) non-small-cell lung cancer (NSCLC) in adults. It is only recommended if the company provides it according |
| to the commercial arrangement. |
| NHS England Commissioned |
RED Obinutuzumab [Gazyvaro] |
| NICE TA513 Recommended as an option for untreated advanced follicular lymphoma(that is, first as induction treatment |
| with chemotherapy, then alone as maintenance therapy), only if: |
| > the person has a Follicular Lymphoma International Prognostic Index score of 2 or more |
| > the company provides obinutuzumab with the discount agreed in the patient access scheme |
| NHS England Commissioned) |
RED Olaparib [Lynparza] |
NICE TA381 Recommended as an option by NICE for maintenance treatment of relapsed, platinum- sensitive, BRCA mutation-
|
positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based
|
| chemotherapy, |
| NICE TA598 Recommended as an option for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian |
| tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
Cancer Drugs Fund
|
| NICE TA620 Recommended as an option for the maintenance treatment of relapsed, platinum-sensitive, high grade epithelial |
| ovarian, fallopian tube or primary peritoneal cancer in adults whose disease has responded to platinum-based |
| chemotherapy only if: |
| > they have a BRCA1 or BRCA2 mutation |
| > they have had 3 or more courses of platinum-based chemotherapy and |
| > the company provides olaparib according to the commercial arrangement Cancer Drugs Fund |
| |
| NICE TA693 Olaparib plus bevacizumab is recommended as an option for use within the Cancer drugs fund as an option for |
| maintenance treatment of advanced International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) |
| high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when: |
| > there has been a complete or partial response after first-line platinum-based chemotherapy plus bevacizumab, and |
| > the cancer is associated with homologous recombination deficiency (HRD). Cancer Drugs Fund |
| |
| |
RED Osimertinib [Tagrisso]
|
| NICE TA653 Recommended as an option for treating epidermal growth factor receptor T790M mutation-positive locally advanced |
| or metastatic non-small-cell lung cancer in adults only if: |
| > their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor and |
| > the company provides osimertinib according to the commercial arrangement |
[Replaces NICE TA416] (NHS England Commissioned )
|
| |
| NICE TA654 Recommended within its marketing authorisation, as an option for untreated locally advanced or metastatic |
| epidermal growth factor receptor mutation-positive non-small-cell lung cancer in adults. |
| [Replaces NICE TA621] (NHS England Commissioned ) |
| |
| NICE TA761 Osimertinib is recommended for use within the Cancer Drugs Fund as adjuvant treatment after complete tumour |
| resection in adults with stage 1b to 3a non‑small‑cell lung cancer (NSCLC) whose tumours have epidermal growth |
| factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. It is recommended only if: |
| > osimertinib is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity and |
| > the company provides osimertinib according to the managed access agreement. |
| |
| |
| |
RED Oxaliplatin injection 50mg, 100mg (NICE indication only)
RED Paclitaxel injection 30mg/5ml (NICE indication only)
|
RED Paclitaxel Iv infusion - in combination with platinum as an option for treating recurrent ovarian cancer in - NICE TA389
|
| RED Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| - an option by NICE TA476 (replaces TA360) |
RED Palbociclib |
NICE TA495 Recommended within its marketing authroisation, with an aromatase inhibitor, as an option for treating
|
| hormone receptor-positive , human epidermal growth receptor 2-negative, locally advanced or metastatic breast |
| cancer as initial endocrine-based therapy in adults. |
| NICE TA619 this NICE TA has been updated and replaced by NICE TA836 |
| NICE TA836 Palbociclib plus fulvestrant is recommended as an option for treating hormone receptor‑positive, HER2‑negative |
| locally advanced or metastatic breast cancer in adults who have had endocrine therapy only if: |
| > exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK4/6) |
| inhibitor and |
| > the company provides it according to the commercial arrangement. |
| NHS England Commissioned |
RED Panitumumab is recommended, as an option for previously untreated metastatic colorectal cancer as per NICE TA 439
|
(updated Sept 2017)
|
RED Panobinostat 20mg tablets - recommended as an option by NICE for treating v multiple myeloma after at least two
|
| previous treatments. NICE TA380 |
RED Pazopanib Tablets, f/c - recommended as a first-line treatment option for people with advanced renal cell carcinoma
|
| in NICE TA215 |
RED Pegaspargase as an option for treating acute lymphoblastic leukaemia in children, young people and adults only when
|
they have untreated newly diagnosed disease, (as part of antineoplastic combination therapy) as recommended in NICE TA408
RED Pembrolizumab
|
NICE TA428 Recommended as an option for treating locally advanced or metastatic PD-L1-positive non-small-cell lung cancer in
|
| adults who have had at least one chemotherapy. (NHS England Commissioned) |
NICE TA519 Recommended as an option for treating locally advanced or metastatic urothelial carcinoma after
|
| platinum-containing chemotherapy. |
| This guidance has been updated and replaced by NICE technology appraisal guidance 692. |
NICE TA522 recommended for use within the Cancer drugs Fund as an option for untreated locally advanced or metastatic
|
| carcinoma in adults when cisplatin-containing chemotherapy is unsuitable |
| (Guidance updated July 2018: The European medicines Agency restricted the use of pembrolizumab for untreated |
| urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. For more information, see the |
| summary of product characteristics for pembrolizumab). (NHS England Cancer Drug Fund) |
NICE TA531 Recommended as an option for untreated PD-L1 positive metastatic non-small-cell lung cancer in adults whose
|
| tumours express PD-L1 (with at least 50% tumour proportion score) and have no epidermal growth factor receptor |
| - or anaplastic lymphoma kinase-positive mutations. |
| (replaces NICE TA447) (NHS England Commissioned) |
NICE TA540 Recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had
|
| brentuximab vedotin and cannot have autologous stem cell transplant (NHS England Cancer Drug Fund) |
NICE TA553 Recommended for use within the Cancer Drug Fund as an option for the adjuvant treatment of Stage III melanoma
|
| with lymph node involvement in adults who have had complete resection. (NHS England Cancer Drug Fund) |
NICE TA557 Recommended for use within the Cancer Drugs Fund, with pemetrexed and platinum chemotherapy, as an option
|
| untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal |
| growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. |
| (NHS England Cancer Drug Fund) |
| NICE TA600 Recommended for use within the Cancer Drugs Fund, with carboplatin and paclitaxel, as an option for untreated |
| metastatic squamous non-small-cell lung cancer in adults only if: |
| > pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and |
| > the company provides pembrolizumab according to the managed access agreement |
| NHS England Cancer Drug Fund |
| NICE TA661 Recommended as an option for untreated metastatic or unresectable recurrent head and neck squamous cell |
| carcinoma in adults whose tumours express PD-L1 with a combined positive score of 1 or more. |
| NHS England Commissioned |
| NICE TA683 Recommended as an option with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous |
| non-small-cell lung cancer in adults whose tumours have no epidermal growth factor receptor-positive or anaplastic |
| lymphoma kinase-positive mutations. This is only if: |
| > it is stopped at 2 years of uninterrupted treatment, or earlier if the disease progresses and |
| > the company provides pembrolizumab according to the commercial arrangement (Cancer Drug Fund) |
| NICE TA709 Recommended as an option for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or |
| mismatch repair (MMR) deficiency in adults, only if: |
| > pembrolizumab is stopped after 2 years and no documented disease progression, and |
| > the company provides pembrolizumab according to the commercial arrangement. |
| NICE TA737 Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy is recommended, within its marketing |
| authorisation, as an option for untreated locally advanced unresectable or metastatic carcinoma of the |
| oesophagus or HER2‑negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 |
| with a combined positive score (CPS) of 10 or more. Pembrolizumab is only recommended if the company |
provides it according to the commercial arrangement. NHS England Commissioned
|
| NICE TA801 Pembrolizumab plus chemotherapy (paclitaxel or nab‑paclitaxel) is recommended as an option for treating |
| triple‑negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy |
| for metastatic disease. It is recommended only if: |
| > the tumours express PD-L1 with a combined positive score (CPS) of 10 or more and an immune cell |
| staining of less than 1%, and |
| > the company provides pembrolizumab according to the commercial arrangement NHS England Commissioned |
| NICE TA830 Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment |
| of renal cell carcinoma at increased risk of recurrence after nephrectomy, with or without metastatic lesion resection, |
| with or without metastatic lesion resection, in adults. It is recommended only if the company provides it according to |
| the commercial arrangement. NHS England Commissioned |
| NICE TA837 Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of |
| completely resected stage 2B or 2C melanoma in people 12 years and over. It is recommended only if the company |
| provides pembrolizumab according to the commercial arrangement. NHS England Commissioned |
| NICE TA851 Pembrolizumab is recommended, within its marketing authorisation, as an option with chemotherapy |
| for neoadjuvant treatment and then continued alone as adjuvant treatment after surgery for adults with triple- |
| negative: |
| > early breast cancer at high risk of recurrence or |
| > locally advanced breast cancer. |
| It is recommended only if the company provides pembrolizumab according to the commercial arrangement. |
| NHS England Commissioned |
| NICE TA904 Pembrolizumab plus lenvatinib is recommended, within its marketing authorisation, for treating advanced or |
| recurrent endometrial cancer in adults: |
| > whose cancer has progressed on or after platinum-based chemotherapy and |
| > who cannot have curative surgery or radiotherapy. |
| Pembrolizumab plus lenvatinib is recommended only if the companies provide them according to the commercial arrangements. |
| NHS England Commissioned |
RED Pemigatinib [Pemazyre® tablets 9mg/13.5mg] NHS England Commissioned |
| NICE TA722 Recommended as an option, within its marketing authorisation, for treating locally advanced or metastatic |
| cholangiocarcinoma with fibroblast growth factor receptor fusion or rearrangement that has progressed after |
| systemic therapy in adults. It is recommended only if the company provides pemigatinib according to the |
| commercial arrangement. |
RED Pentostatin injection 10mg |
RED Pertuzumab solution for infusion 30mg/mL - an option for the neoadjuvant treatment of adults with human epidermal
|
| growth factor receptor 2 (HER2)‑positive breast cancer, in combination with trastuzumab and chemotherapy, |
| as per NICE TA424 |
RED Pertuzumab HER2-positive metastatic or locally recurrent unrescetable breast cancer in adults who have not had
|
| previous anti‑HER2 therapy or chemotherapy for their metastatic disease (in combination with trastuzumab and |
| docetaxel - NICE TA509 |
| RED Pertuzumab - NICE TA569 - Recommended, with intarvenous tarstuzumab and chemotherpay, for the adjuvant |
treatment of human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults, only if:
|
| > they have lymph node-positive disease |
| > the company provides it according to the commercial arrangement |
| NHS England Commissioned |
| RED Polatuzumab vedotin [Polivy] |
| NICE TA649 Polatuzumab vedotin with rituximab and bendamustine is recommended, within its marketing authorisation, as an option for treating relapsed |
| or refractory diffuse large B‑cell lymphoma in adults who cannot have a haematopoietic stem cell transplant. |
| It is recommended only if the company provides polatuzumab vedotin according to the commercial arrangement. NHS England Commissioned |
| NICE TA874 Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisolone (R‑CHP) is recommended for untreated diffuse |
| large B-cell lymphoma (DLBCL) in adults, only if |
| > they have an International Prognostic Index (IPI) score of 2 to 5 |
| > the company provides it according to the commercial arrangement. NHS England Commissioned |
| |
RED Ponatinib - Recommended as per NICE TA451 as an option for treating chronic-accelerated -or blast - phase chronic |
myeloid leukaemia in adults. (NHS England Commissioned)
|
RED Procarbazine capsules 50mg
|
RED Radium-223 dichloride recommended as an option by NICE for treating hormone-relapsed pro state cancer
|
with bone metastases. NICE TA376
|
| |
| RED Ravulizumab [Ultomiris® conc for solution for infusion] |
| NICE TA698 Recommended within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria in |
| adults: |
| > with haemolysis with clinical symptoms suggesting high disease activity, or |
| > whose disease is clinically stable after having eculizumab for at least 6 months, and |
| > the company provides it according to the commercial arrangement |
| NHS England Commissioned |
| |
|
| RED Regorafenib (Stivarga) |
| NICE TA488 |
| RED Regorafenib recommended as an option for treating unresectable or metastatic gastrointestinal stromal tumours |
| in adults whose disease has progressed on, or who are intolerant to, prior treatment with imitinib and sunitinib |
| NHS England Commissioned |
| NICE TA555 |
| RED Regorafenib is recommended as an option for treating advanced unrescetable hepatocellular carcinoma in adults |
| who have had sorafenib, only if: |
| > they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance |
| status of 0 or 1 and |
| > the company provides it according to the commercial arrangement. |
| NICE TA866 |
| RED Regorafenib is recommended, within its marketing authorisation, as an option for metastatic colorectal cancer in adults who have had previous |
| previous treatment (including fluoropyrimidine-based chemotherapy, anti‑VEGF therapy and anti‑EGFR therapy) or when these treatments are |
| unsuitable. Regorafenib is only recommended if the company provides it according to the commercial arrangement. |
| NHS England Commissioned |
RED Ribociclib (Kisqali) |
NICE TA496 with an aromatase inhibitor, is recommended within its marketing authorisation, as an option for treating
|
| hormone receptor-positive, human epidermal growth factor receptor 2‑negative, locally advanced or metastatic |
| breast cancer as initial endocrine-based therapy in adults. Ribociclib is recommended only if the company provides |
| it with the discount agreed in the patient access scheme. |
| NICE TA593 with fulvestrant, is recommended for use within the Cancer Drug Fund as an option for treating hormone receptor- |
| positive, human epidermal growth factor receptor (HER2)-negative, locally advanced or metastatic breast cancer in |
| people who have had previous endocrine therapy only if: |
| > exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 |
| (CDK 4/6) inhibitor and |
| > the conditions in the managed access agreement for ribociclib with fulvestrant are followed. |
| NICE TA687 Recommended as an option, plus fulvestrant , for treating hormone receptor-positive, human epidermal growth factor |
| receptor 2 (HER-2) - negative, locally advanced or metastatic breast cancer in adults who have had previous |
| endocrine therapy only if: |
| > examestane plus everolimus is the most appropriate alternative to a cyclin-depnedent kinase 4 and 6 (CDK 4/6) |
| inhibitor, and |
| > the company provides ribociclib according to the commercial arrangement (Cancer Drug Fund) |
RED Rucaparib |
| NICE TA611 Recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum- |
| sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to |
| platinum-based chemotherapy in adults, only if the conditions in the managed access agreement for rucaparib |
| are followed. (Cancer Drug Fund) |
RED Ruxolitinib tablets 5mg,10mg.15mg,20mg NICE TA386
|
| |
RED Selpercatinib |
| NICE TA742 Recommended for use within the Cancer drugs Fund, as an option for treating: |
| > advanced RET fusion-positive thyroid cancer in adults who need systemic therapy after sorafenib or lenvatinib |
| > advanced RET-mutant medullary thyroid cancer in people 12 years and older who need systemic therapy after |
| cabozanitinib or vandetanib |
| It is recommended only if the conditions in the managed access agreement are followed. (Cancer Drug Fund) |
| NICE TA760 Recommended for use within the Cancer drugs Fund, as an option for treating RET Fusion-positive advanced |
| non-small-cell lung cancer in adults who need systemic therapy after immunotherapy, platinum-based |
| chemotherapy or both. It is recommended only if the conditions in the managed access agreement are followed. |
| Cancer Drugs Fund |
RED Sorafenib tablets 200mg recommended as an option for treating hepatocellular carcinoma only for people with
|
| Child-Pugh A liver impairment as per NICE TA474 |
RED Sotorasib |
| NICE TA781 Sotorasib is recommended for use within the Cancer Drugs Fund as an option for treating KRAS G12C mutation- |
positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or
|
| cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy. It is recommended only if the |
| conditions in the managed access agreement for sotorasib are followed. |
| Cancer Drugs Fund |
RED Sunitinib capsules 12.5mg, 25mg, 50mg
|
| RED Sunitinib capsules 12.5mg, 25mg, 50mg recommended as an option treating well, or moderately differentiated |
| unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease. |
| as per NICE TA 449 NHS England Commissioned |
RED Temozolomide capsules 5mg, 20mg, 100mg,140mg, 180mg,250mg NICE TA23 (updated March 2016)
|
| |
RED Tepotinib |
| NICE TA789 Recommended, within its marketing authorisation, as an option for treating advanced non-small-cell lung cancer with |
| NETex14 skipping alterations in adults, only if the company provides tepotinib according to the commercial |
| agreement. NHS England Commissioned |
RED Tisagenlecleucal is recommended for use within the cancer drug fund as an option for treating relapsed or refractory |
| B-cell acute lymphoblastic leukaemia in people aged up to 25 years , as per NICE TA554 Cancer Drug Fund |
RED Tivozanib - an option in advanced renal cell carcinoma in adults as per NICE TA512 NHS England Commissioned |
RED Topotecan infusion Ovarian cancer (NICE TA91)
|
RED Topotecan infusion cervical cancer, recurrent (NHS England Commissioned)
|
RED Trabectedin powder for concentrate 0.25mg, 1mg (Yondelis®)
|
NICE TA185 [updated February 2021]
|
| Recommended as a treatment option for people with advanced soft tissue sarcoma if: |
| > treatment with anthracyclines and ifosfamide has failed or |
| > they are intolerant of or have contraindications for treatment with anthracyclines and ifosfamide |
| > Trabdectedin is only recommended if the company provides it according to the commercial arramgement |
| (NHS England Commissioned) |
RED Trametininb tablets 0.5mg, 2mg as an option by NICE for treating unresectable or metastatic melanoma in
|
combination with darbrafenib - NICE TA396
|
RED Trastuzumab |
| NICE TA34 Trastuzumab in combination with paclitaxel (combination trastuzumab is currently only licensed for use with |
| paclitaxel) is recommended as an option for people with tumours expressing human epidermal growth factor |
| receptor 2 (HER2) scored at levels of 3+ who have not received chemotherapy for metastatic breast cancer and in |
| whom anthracycline treatment is inappropriate. |
| NICE TA208 Trastusumab [Herceptin], in combination with cisplatin and capecitabine or 5-fluorouracil, is recommended as an |
| option for the treatment of people with human epidermal growth factor receptor 2 (HER2_-positive metastatic |
| adenocarcinoma of the stomach or gastro-oesophageal junction who: |
| ° have not received prior treatment for their metastatic disease and |
| ° have tumours expressing hig levels of HERs as defined by a positive immunohistochemistry score of 3 (IHC3 |
| positive) |
RED Trastuzumab emtansine [Kadcyla®] |
NICE TA458 Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for treating a human
|
| epidermal growth factor receptor (HER2) - positive, unrescetable, locally advanced or metastatic breast cancer in |
| adults who previously received trastuzumab and a taxane, separately or in combination - updated (replaces TA371). |
| Cancer Drug Fund |
| NICE TA632 Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for the adjuvant |
| treatment of human epidermal growth g=factor receptor 2 (HER2)- positive early breast cancer in adults who have had |
| residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy. |
| It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement |
| NHS England Commissioned |
RED Trastuzumab deruxtecan [Enhertu®] |
| NICE TA704 Trastuzumab deruxtecan is recommended for use within the Cancer drugs Fund as an option for treating HER2- |
| positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. It is recommended |
| only if the conditions of the managed access agreement are followed. Cancer Drugs Fund |
| |
| NICE TA862 Trastuzumab deruxtecan is recommended with managed access as an option for treating HER2‑positive unresectable or metastatic breast cancer |
| after 1 or more anti-HER2 treatments in adults. It is only recommended if the conditions in the managed access agreement for trastuzumab |
| deruxtecan are followed. Cancer Drugs Fund |
RED Tretinoin capsules 10mg
|
| (Consultant haematologist only – use whilst waiting transfer to specialist centre - see relevant protocol) |
RED Trifluridine-tipiracil tablets 15mg, 20mg
|
NICE TA405 Recommended as an option, within its marketing authorisation, as an option for treating metastatic colorectal cancer,
|
| that is: |
| > in adults who have had previous treatment with available therapies including fluorpyrimidine-, oxaliplatin- or |
| irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor |
| receptor agents, or when these therapies are not suitable, and |
| > only when the company provides trufluridine-tipiracil with the discount agreed i the patient access scheme |
| NICE TA852 Recommended, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro- |
oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimens.
|
| It is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement. |
| This guidance updates and replaces NICE TA699 NHS England Commissioned |
RED Tucatinib tablets 50mg,100mg |
| NICE TA786 Recommended with trastuzumab and capecitabine, within its marketing authorisation, as an option for treating |
| HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies |
| only if the company provides tucatinib according to the commercial arrangement |
| NHS England Commissioned |
RED Vemfurafenib tablets 240mg |
| NICE TA269 Recommended as an option for treating BRAF V600 mutation-positive unresectable or metastatic melanoma only if |
| the manufacturer provides vemurafenib with the discount agreed in the patient access scheme |
RED Venetoclax [Venclyxto] |
| NICE TA487 This guidance has been updated and replaced by NICE TA796 |
NICE TA561 Venetoclax with rituximab - recommended, within its marketing authorisation, as an option for treating chronic
|
| lymphocytic leukaemia in adults who have had at least 1 previous therapy. (Cancer Drugs Fund) |
| NICE TA663 Venetoclax plus obinutuzumab is recommended as an option for untreated chronic lymphocytic leukaemia [CLL] in |
| adults, only if: |
| > there is a 17p deletion or TP53 mutation, or |
| > there is no 17p deletion ot TP53 mutation, and fludarabine plus cyclophosphamide and rituximab [FCR], or |
| bendamustine plus rituximab [BR], is unsuitable, and |
| > the companies provide the drugs according to the commercial arrangements. |
| Venetoclax plus obinutuzumab is recommended for use within the Cancer drugs Fund as an option for untreated CLL |
| in adults, only if: |
| > there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and |
| > the conditions in the managed access agreement for venetoclax plus obinutuxumab are followed |
| |
| NICE TA765 Recommended as an option with azacitidine, within its marketing authorisation, as an option for unttreate acute |
| myeloid leukaemia in adults when intensive chemotherapy is unsuitable. It is recommended only if the company |
| provides venetoclax according to the commercial arrangement. NHS England Commissioned |
| |
| NICE TA787 Recommended as an option, with low dose cytarabine, for untreated acute myeloid leukaemia in adults when |
| intensive chemotherapy is unsuitable, only if: |
| > they have over 30% bone marrow blasts |
| > the company provides venetoclax according to the commercial agreement |
| NHS England Commissioned |
| NICE TA796 Venetoclax monotherapy is recommended, within its marketing authorisation, for treating chronic lymphocytic |
| leukaemia in adults: |
| > with a 17p deletion or TP53 mutation and when a B-cell receptor pathway inhibitor is unsuitable, or whose |
| disease has progressed after a B=cell receptor pathway inhibitor ir |
| > without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo-immunotherapy |
| and a B-cell receptor pathway inhibitor |
| It is recommended only if the company provides venetoclax according to the commercial arrangement |
| This guidance updates and replaces NICE TA487 NHS England Commissioned |
| |
RED Zanubrutinib (Brukinsa) NHS England Commissioned |
| NICE TA833 recommended as an option for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 treatment, only if: |
| > bendamustine plus rituximab is also suitable and |
| > the company provides it according to the commercial arrangement. |
| |
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
